

Correction of Figures in Interim Report for the First Quarter 2025/26

When publishing the interim report for the company, it was discovered that some of the total sums in the income statement show the wrong amounts. The sum of Net Sales and Work Performed by Own Use and Activated has mistakenly included Other operating income. Moreover, Other operating expenses was summed erroneously leading to that the sum for Total Expenses showed an incorrect amount. None of the company KPI's changes from these corrections.

Therefore, the company makes the following corrections:

- The total sum of income changes to 24,834 from 25,914.
- Other operational income changes to -329 from -1,409.
- Total expenses changes to -37,262 from -38,342

The updated interim report can be found here:

<https://integrum.se/investor-relations/financial-reports-calendar/>

This disclosure contains information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on September 1, 2025 at 13:15am CET.

For more information please contact:

Jörgen Svanström, CFO. Phone: +46 70 734 96 60, E-mail: jorgen.svanstrom@integrum.se

Certified Adviser:

The Company's Certified Adviser is DNB Carnegie Investment Bank AB.

About integrum

Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA™ Implant System has helped

improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit <https://integrum.se/>.